[PDF][PDF] Management of progressive radioiodine-refractory thyroid carcinoma: current perspective
A Nervo, F Retta, A Ragni, A Piovesan… - Cancer Management …, 2023 - Taylor & Francis
Patients with thyroid cancer (TC) usually have an excellent prognosis; however, 5–10% of
them develop an advanced disease. The prognosis of this subgroup is still favourable if the …
them develop an advanced disease. The prognosis of this subgroup is still favourable if the …
Current standards in treatment of radioiodine refractory thyroid cancer
S Narayanan, AD Colevas - Current treatment options in oncology, 2016 - Springer
Opinion Statement Radioiodine refractory differentiated thyroid cancer (RAI-R DTC) is a
challenging malignancy with limited prognosis and treatment options. Recently, clinical trials …
challenging malignancy with limited prognosis and treatment options. Recently, clinical trials …
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives
O Karapanou, G Simeakis… - Endocrine-Related …, 2022 - erc.bioscientifica.com
During the last decades the knowledge on follicular cell-derived thyroid cancer (TC)
molecular biology has led to the evolution of a number of novel therapies for these tumors …
molecular biology has led to the evolution of a number of novel therapies for these tumors …
[HTML][HTML] New approaches for patients with advanced radioiodine-refractory thyroid cancer
The cumulative evidence over the past decades has shown that the incidence of
differentiated thyroid carcinoma (DTC) has exponentially increased. Approximately 10% of …
differentiated thyroid carcinoma (DTC) has exponentially increased. Approximately 10% of …
Real-world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer
VF Koehler, E Berg, P Adam, GL Weber, A Pfestroff… - Thyroid, 2021 - liebertpub.com
Background: The management of patients with locally advanced or metastatic differentiated
thyroid cancer (DTC) that is refractory to radioiodine (RAI) remains a therapeutic challenge …
thyroid cancer (DTC) that is refractory to radioiodine (RAI) remains a therapeutic challenge …
Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid …
J Capdevila, JC Galofré, E Grande… - Clinical and …, 2017 - Springer
Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid
cancer (DTC) accounts for more than 90% of all malignancies and its incidence has been …
cancer (DTC) accounts for more than 90% of all malignancies and its incidence has been …
Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer
F Worden - Therapeutic advances in medical oncology, 2014 - journals.sagepub.com
Until recently, no truly effective treatment options have existed for patients with radioactive
iodine (RAI)-refractory differentiated thyroid cancer (DTC), a serious disease with poor …
iodine (RAI)-refractory differentiated thyroid cancer (DTC), a serious disease with poor …
Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer
C Cortas, H Charalambous - Life, 2023 - mdpi.com
Patients with differentiated thyroid cancer usually present with early-stage disease and
undergo surgery followed by adjuvant radioactive iodine ablation, resulting in excellent …
undergo surgery followed by adjuvant radioactive iodine ablation, resulting in excellent …
Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions
F Pacini, Y Ito, M Luster, F Pitoia… - Expert Review of …, 2012 - Taylor & Francis
Approximately 90% of thyroid cancers are differentiated (DTCs) and have papillary, follicular
or Hürthle cell morphology. Although treatment with surgery and radioactive iodine (I-131; …
or Hürthle cell morphology. Although treatment with surgery and radioactive iodine (I-131; …
Questions and controversies in the clinical application of tyrosine kinase inhibitors to treat patients with radioiodine-refractory differentiated thyroid carcinoma: expert …
FA Verburg, H Amthauer, I Binse, I Brink… - Hormone and …, 2021 - thieme-connect.com
Notwithstanding regulatory approval of lenvatinib and sorafenib to treat radioiodine-
refractory differentiated thyroid carcinoma (RAI-R DTC), important questions and …
refractory differentiated thyroid carcinoma (RAI-R DTC), important questions and …